Galera Therapeutics Insiders

GRTXDelisted Stock  USD 2.58  0.19  6.86%   
Galera Therapeutics employs about 7 people. The company is managed by 10 executives with a total tenure of roughly 17 years, averaging almost 1.0 years of service per executive, having 0.7 employees per reported executive. Break down of Galera Therapeutics' management performance can provide insight into the company performance.
Mel MD  CEO
President CEO
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Galera Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.5929) % which means that it has lost $0.5929 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.6311) %, meaning that it created substantial loss on money invested by shareholders. Galera Therapeutics' management efficiency ratios could be used to measure how well Galera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Galera Therapeutics Workforce Comparison

Galera Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,077. Galera Therapeutics maintains roughly 7.0 in number of employees contributing less than 1% to equities under Health Care industry.

Galera Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Galera Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Galera Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Galera Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Galera Therapeutics Notable Stakeholders

A Galera Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Galera Therapeutics often face trade-offs trying to please all of them. Galera Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Galera Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Mel MDPresident CEOProfile
Dr MBACoFounder COOProfile
Jennifer EsqChief SecretaryProfile
Andie CollierChief OfficerProfile
FACS FACSChief OfficerProfile
Christopher DegnanChief OfficerProfile
PharmD MBAChief OfficerProfile
Jon MDEx OfficerProfile
Dennis RileyEmeritus OfficerProfile
Judy SchnyderSenior ManagementProfile

About Galera Therapeutics Management Performance

The success or failure of an entity such as Galera Therapeutics often depends on how effective the management is. Galera Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Galera management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Galera management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Galera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.
Please note, the imprecision that can be found in Galera Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Galera Therapeutics. Check Galera Therapeutics' Beneish M Score to see the likelihood of Galera Therapeutics' management manipulating its earnings.

Galera Therapeutics Workforce Analysis

Traditionally, organizations such as Galera Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Galera Therapeutics within its industry.

Galera Therapeutics Manpower Efficiency

Return on Galera Therapeutics Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee8.4M
Net Loss Per Executive5.9M
Working Capital Per Employee2.4M
Working Capital Per Executive1.7M
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Stocks Directory module to find actively traded stocks across global markets.

Other Consideration for investing in Galera Pink Sheet

If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities